Time in Range: How to Measure It, How to Report It, and Its Practical Application in Clinical Decision-Making

Overview

Journal Clin Diabetes

Specialty Endocrinology

Date 2021 Jan 1

PMID 33384469

Citations 12

Authors

Eugene E Wright Jr

Kayla Morgan

Danny K Fu

Nick Wilkins

William J Guffey

Affiliations

Soon will be listed here.

Abstract

The A1C metric has been the gold standard for assessing glycemia for decades. This biologic assay, based on averaging, is fraught with limitations and may be giving way to more holistic approaches. This article reviews glycemic time in range as the new standard for assessing patients with continuous glucose monitoring data. Information from the International Consensus Group on Time in Range will be summarized.

Citing Articles

Glycemic variability and quality of life outcomes after changing to hybrid closed-loop system in Japanese individuals with type 1 diabetes using a conventional predictive low-glucose suspended insulin pump system.

Fuchigami A, Kojimahara Y, Yoshikawa F, Higa M, Ichijyo T, Ikehara K Diabetol Int. 2025; 16(1):123-130.

PMID: 39877442 PMC: 11769885. DOI: 10.1007/s13340-024-00778-7.

Biotechnology Revolution Shaping the Future of Diabetes Management.

Kundnani N, Lolescu B, Dinu A, Berceanu-Vaduva D, Dumitrescu P, Tamas T Biomolecules. 2025; 14(12.

PMID: 39766270 PMC: 11674738. DOI: 10.3390/biom14121563.

Impact of allulose on blood glucose in type 2 diabetes: A meta-analysis of clinical trials.

Ayesh H, Suhail S, Ayesh S Metabol Open. 2024; 24:100329.

PMID: 39583955 PMC: 11585728. DOI: 10.1016/j.metop.2024.100329.

Clinical perspective on innovative insulin delivery technologies in diabetes management.

Kockaya G, Battelino T, Petrovski G, Jendle J, Sarman B, Elbarbary N Front Endocrinol (Lausanne). 2024; 15:1308319.

PMID: 39411309 PMC: 11473347. DOI: 10.3389/fendo.2024.1308319.

Enhancement of Ambulatory Glucose Profile for Decision Assistance and Treatment Adjustments.

Satuluri V, Ponnusamy V Diagnostics (Basel). 2024; 14(4).

PMID: 38396474 PMC: 10888350. DOI: 10.3390/diagnostics14040436.

References

Lipska K, Warton E, Huang E, Moffet H, Inzucchi S, Krumholz H . HbA1c and risk of severe hypoglycemia in type 2 diabetes: the Diabetes and Aging Study. Diabetes Care. 2013; 36(11):3535-42. PMC: 3816866. DOI: 10.2337/dc13-0610. View

. Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2016; 40(1):155-157. DOI: 10.2337/dc16-2215. View

Agiostratidou G, Anhalt H, Ball D, Blonde L, Gourgari E, Harriman K . Standardizing Clinically Meaningful Outcome Measures Beyond HbA for Type 1 Diabetes: A Consensus Report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the.... Diabetes Care. 2017; 40(12):1622-1630. PMC: 5864122. DOI: 10.2337/dc17-1624. View

Miller M, Bonds D, Gerstein H, Seaquist E, Bergenstal R, Calles-Escandon J . The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ. 2010; 340:b5444. PMC: 2803743. DOI: 10.1136/bmj.b5444. View

Gillery P . A history of HbA1c through Clinical Chemistry and Laboratory Medicine. Clin Chem Lab Med. 2012; 51(1):65-74. DOI: 10.1515/cclm-2012-0548. View

Klonoff D . ADAG study group data links A1C levels with empirically measured blood glucose values - new treatment guidelines will now be needed. J Diabetes Sci Technol. 2014; 8(3):439-43. PMC: 4455453. DOI: 10.1177/1932296814529638. View

Gerstein H, Miller M, Byington R, Goff Jr D, Thomas Bigger J, Buse J . Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358(24):2545-59. PMC: 4551392. DOI: 10.1056/NEJMoa0802743. View

Lenters-Westra E, Slingerland R . Hemoglobin A1c determination in the A1C-Derived Average Glucose (ADAG) study. Clin Chem Lab Med. 2008; 46(11):1617-23. DOI: 10.1515/CCLM.2008.322. View

Koehler C, Henkel E, LEONHARDT W, Fuecker K, Hanefeld M . Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care. 2000; 23(12):1830-4. DOI: 10.2337/diacare.23.12.1830. View

10.

Whitmer R, Karter A, Yaffe K, Quesenberry Jr C, Selby J . Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009; 301(15):1565-72. PMC: 2782622. DOI: 10.1001/jama.2009.460. View

11.

Bergenstal R, Beck R, Close K, Grunberger G, Sacks D, Kowalski A . Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring. Diabetes Care. 2018; 41(11):2275-2280. PMC: 6196826. DOI: 10.2337/dc18-1581. View

12.

Guo Q, Zang P, Xu S, Song W, Zhang Z, Liu C . Time in Range, as a Novel Metric of Glycemic Control, Is Reversely Associated with Presence of Diabetic Cardiovascular Autonomic Neuropathy Independent of HbA1c in Chinese Type 2 Diabetes. J Diabetes Res. 2020; 2020:5817074. PMC: 7026737. DOI: 10.1155/2020/5817074. View

13.

Nathan D, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine R . Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008; 31(8):1473-8. PMC: 2742903. DOI: 10.2337/dc08-0545. View

14.

Lachin J, Genuth S, Cleary P, Davis M, Nathan D . Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000; 342(6):381-9. PMC: 2630213. DOI: 10.1056/NEJM200002103420603. View

15.

Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

16.

Beck R, Bergenstal R, Riddlesworth T, Kollman C, Li Z, Brown A . Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials. Diabetes Care. 2018; 42(3):400-405. PMC: 6905478. DOI: 10.2337/dc18-1444. View

17.

Kovatchev B . Metrics for glycaemic control - from HbA to continuous glucose monitoring. Nat Rev Endocrinol. 2017; 13(7):425-436. DOI: 10.1038/nrendo.2017.3. View

18.

Beck R, Bergenstal R, Cheng P, Kollman C, Carlson A, Johnson M . The Relationships Between Time in Range, Hyperglycemia Metrics, and HbA1c. J Diabetes Sci Technol. 2019; 13(4):614-626. PMC: 6610606. DOI: 10.1177/1932296818822496. View

19.

Haffner S . The importance of postprandial hyperglycaemia in development of cardiovascular disease in people with diabetes: point. Int J Clin Pract Suppl. 2001; (123):24-6. View

20.

Green A, Fox K, Grandy S . Self-reported hypoglycemia and impact on quality of life and depression among adults with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2012; 96(3):313-8. DOI: 10.1016/j.diabres.2012.01.002. View